WA-EKATA
7.4.2021 15:02:11 CEST | Business Wire | Press release
Ekata , the leader in global digital identity data, today announced its Merchant Onboarding solution to help payment service providers (PSPs), B2B lenders and marketplaces onboard the growing number of micro-merchants and sole proprietors across the globe faster and with more confidence. The lack of commercial track record for these new small businesses makes it difficult for PSPs and lenders to quickly and confidently approve them using traditional methods of risk assessment. Ekata set out to help customers enhance their existing models with risk indicators that show fraud likelihood based on a mix of comprehensive customer data tests and best-practice considerations. By providing unique data that cross-checks the connection between businesses and the individuals behind them, Ekata’s new merchant onboarding solution enables organizations to confidently assess risk at scale, automate onboarding workflows, and reduce time spent in manual review.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210407005320/en/
The global pandemic accelerated an existing trend of individuals establishing their own small businesses. In the U.S. alone there are 30 million small merchants and an additional 40 million individuals who became independent contractors in 2020. Similarly, Europe has 25.1 million small businesses and a growing 33 million sole proprietors . On the tailwinds of this trend, Covid-19 added some additional unexpected fuel: in October 2020, the U.S. Census Bureau published the business-formation statistics for the third quarter of 2020. Third-quarter 2020 business applications rose by 77.4% from June to September .
With this massive growth comes an increasing demand for quick and effective onboarding of these merchants by PSPs and lending institutions. Companies like Stripe, Square, PayPal and others have set a new standard by cutting onboarding times from 2-3 days to just minutes, often threatening the business viability of other PSPs whose processes and risk assessments can’t keep up with their pace. In this intensely competitive market, Ekata’s solution helps PSPs and lenders respond to the increasing expectations for speedier onboarding.
“Merchants today have plenty of options and will quickly turn to another payment service provider if an organization adds too much friction at onboarding or takes too long on approvals ,” says Beth Shulkin, Ekata’s VP of Global Marketing. “This is much more than a customer experience issue for PSPs and lenders; losing the lifetime value of a merchant has real bottom-line impact .”
Ekata’s holistic solution is designed to solve both sides of the flow: automating the onboarding process via APIs and enabling more efficient manual reviews with a SaaS solution. Our API integrates easily with existing rules or machine learning-based risk models, and our SaaS product quickly surfaces correlations between key individual and business identity attributes on easy-to-read dashboards.
Key benefits of the Merchant Onboarding solution include:
- Onboard micro-merchants and sole proprietor businesses with higher confidence: With individual, business, and unique cross-linked signals, Ekata customers can build trusted risk profiles for micro-merchants and sole proprietors that lack the typical track record - verifying information and approving or rejecting applications with confidence.
- Quickly route good customers for automated underwriting: Businesses can shift low-risk merchant applications away from high friction onboarding steps such as supplemental document collection and manual review, towards automated approval, which gets these customers onboard and generating revenue as quickly as possible. They can then focus on high-risk customers that need additional documentation or manual review.
- Reduce time spent in manual review: Businesses can quickly view a key set of individual and business data, reducing the time needed to research data across multiple sources and helping the reviewer make a faster, more efficient, and more accurate decision.
For additional information on Ekata’s Merchant Onboarding API, visit here . To learn more about Ekata’s Merchant Review, visit here .
About Ekata
Ekata provides global identity verification via APIs and a SaaS solution to provide businesses worldwide the ability to link any digital transaction to the human behind it. The Ekata product suite is powered by the Ekata Identity Engine, our proprietary, intellectual property, that uses unique datasets from the Ekata Identity Graph and the Ekata Identity Network that provides identity verification data with consistent results across the globe, in industry-leading response times, to enable businesses around the world like AliPay, Microsoft, Stripe, and Airbnb to fight fraud, reduce false declines, and make accurate risk decisions about their customers faster than the blink of an eye.
Ekata is a trademark of Ekata, Inc. All other trade names, trademarks and registered trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005320/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
